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Introduction {#sec1}
============

Tauopathies including frontotemporal dementia (FTD) and Alzheimer disease (AD), are a group of neurodegenerative diseases characterized by the hyperphosphorylation and accumulation of the microtubule-associated protein tau in the human brain ([@bib38]). Tau is predominantly expressed in neuronal axons where it controls the polymerization and stabilization of the microtubules while it also regulates axonal transport ([@bib8], [@bib21]). However, under pathological conditions, several *MAPT* gene mutations have been linked to hyperphosphorylation and aggregation of tau into neurofibrillary tangles (NFTs) resulting in FTD ([@bib18]).

Alternative splicing of exon 2, 3, and 10 of the *MAPT* gene on chromosome 17 leads to the expression of six different tau isoforms in the adult human brain, with the longest isoform (2N4R) harboring two N-terminal insertions (exon 2 and 3) and the inclusion of a fourth repeat (exon 10) in tau\'s microtubule binding domain. The expression of the different isoforms is transcriptionally regulated with only the shortest isoform (0N3R) being expressed at embryonic stages and during development ([@bib23]). The function and neuronal expression pattern of these different tau isoforms remain to be elucidated, although correct splicing seems to be necessary to keep neurons functional, as unbalanced 4R:3R tau ratios are linked with neurodegenerative disorders such as FTD and Huntington disease ([@bib18], [@bib9], [@bib10]). For example, *MAPT* mutations that promote the inclusion of exon 10 appear to be sufficient to trigger disease ([@bib18]).

Over the past years, human induced pluripotent stem cells (iPSCs) have been extensively used to generate better models for human diseases, including neurodegenerative disorders leading to dementia. Human iPSCs can be differentiated into various neuronal subtypes, including cortical neurons, which are known to be affected in FTD ([@bib4]). However, we and others have shown that wild-type iPSC-derived cortical neurons mainly express the embryonic tau isoform that lacks exon 10, even after extended culturing time ([@bib39], [@bib40]), making it challenging to study exon 10-related tauopathies in this model. Therefore, we introduced the pathogenic IVS10+16 mutation, shown to increase the inclusion of exon 10 ([@bib14], [@bib39]) in iPSCs from a healthy donor using zinc finger nuclease (ZFN) technology. Extensive characterization of differentiated IVS10+16 tau neurons compared with the isogenic control revealed neuronal subtype differences accompanied by a reduced neural progenitor (NPC) proliferation potential and aberrant WNT/SHH signaling, already at the earliest stages of neurodevelopment. Additionally, and with the aim to model an early-onset and more aggressive FTDP-17-linked tauopathy ([@bib5], [@bib2]), we introduced the pro-aggregant P301S point mutation in exon 10. Specific P301S-related phenotypes such as increased calcium burst frequency, reduced lysosomal acidy, tau oligomerization, and neurodegeneration could be observed within weeks after plating of NPCs.

Both *MAPT* IVS10+16 and IVS10+16/P301S iPSCs, in conjunction with their parental isogenic wild-type cells, are useful tools to further elucidate the role of the IVS10+16 mutation, the P301S mutation, and the mechanisms underlying FTDP-17 and other tauopathies.

Results {#sec2}
=======

ZFN-Engineered *MAPT* IVS10+16 and IVS10+16/P301S iPSCs Are Pluripotent and Have a Normal Karyotype {#sec2.1}
---------------------------------------------------------------------------------------------------

With the aim to generate improved translational human tauopathy models, we used ZFN technology to introduce the FTDP-17-associated *MAPT* IVS10+16 and P301S mutations into commercially available control hiPSCs (iPSC0028) from Sigma. The intronic *MAPT* IVS10+16 mutation was chosen to ensure the inclusion of exon 10 to accelerate and increase the expression of more mature 4R isoforms of tau. The P301S mutation, in *MAPT* exon 10, was selected for its potency to induce tau pathology ([@bib2], [@bib5]). Two single-mutation iPSC lines were generated: mono-allelic IVS10+16 (+/−) and biallelic IVS10+16 (+/+). Next to these single-mutant lines, also a double-mutant IVS10+16 (+/+)/P301S (+/+) iPSC line, biallelic for both mutations, was generated to ensure the expression of P301S in all 4R tau isoforms. The genetically engineered iPSCs were fully characterized. G-banding reveals a normal karyotype ([Figure 1](#fig1){ref-type="fig"}A), while pluripotency is confirmed using immunofluorescent staining for OCT4 and NANOG ([Figure 1](#fig1){ref-type="fig"}B). Finally, Sanger sequencing confirms the presence of the mono- and biallelic IVS10+16 mutation and the biallelic P301S point mutation ([Figure 1](#fig1){ref-type="fig"}C).Figure 1ZFN-Engineered *MAPT* IVS10+16 and IVS10+16/P301S iPSCs Are Pluripotent and Have a Normal Karyotype(A) G-banding shows a normal karyotype for all three mutant iPSC lines.(B) Immunofluorescent staining for the pluripotency markers OCT4 and NANOG in combination with the nuclear marker DAPI. Scale bars represent 100 μm.(C) The result of Sanger sequencing showing the iPSC clones with mono-or biallelic IVS10+16 (C\>T) mutations and the iPSC clone with a biallelic P301S (C\>T) mutation and biallelic IVS10+16 mutation. (C\>T) mutations are indicated with red arrows.

IVS10+16 Tau Neurons Display Increased Inclusion of Exon 10 on mRNA and Protein Levels Compared with the Isogenic Control {#sec2.2}
-------------------------------------------------------------------------------------------------------------------------

To validate whether the intronic *MAPT* IVS10+16 mutation increases the inclusion of exon 10, reflected by increased 4R tau expression, neurons were generated using a well-established cortical differentiation protocol ([@bib24], [@bib36]). The inclusion of *MAPT* exon 10 and the amount of total tau were evaluated over time at the mRNA level using RT-qPCR. As previously shown by us and others ([@bib39], [@bib40]), we failed to detect 4R tau mRNA (*MAPT* exon 10) in control neurons at day *in vitro* (DIV) 80. In contrast, in all *MAPT* IVS10+16 and IVS10+16/P301S clones, 4R tau mRNA is expressed from the NPC stage onward, with increasing levels after further differentiation into neurons ([Figure 2](#fig2){ref-type="fig"}A). The mRNA for total *MAPT* and 3R tau (*MAPT* without exon 10) also increases over time ([Figures 2](#fig2){ref-type="fig"}B and 2C). The presence of tau protein is confirmed using western blot and immunofluorescent staining ([Figures 2](#fig2){ref-type="fig"}D and 2E), and shows no difference between control and mutant neurons at DIV80. However, there is more tau protein expressed in IVS10+16 mutant neurons at earlier time points (DIV51 and DIV65; p \< 0.0001 for both; [Figure S1](#mmc1){ref-type="supplementary-material"}) and in general there is more tau protein expressed in neurons compared with NPCs (p \< 0.0001 for both control and IVS10+16 neurons; [Figure S1](#mmc1){ref-type="supplementary-material"}). When looking at tau phosphorylation, we observe increased levels of phosphorylation at epitopes Ser396/Ser404 (PHF1) and Thr181 (AT270) in IVS10+16 neurons compared with control neurons 5 and 7 weeks after plating (DIV65 and DIV80; p \< 0.05, IVS10+16 versus control; [Figure S1](#mmc1){ref-type="supplementary-material"}). Finally, neuronal expression of 4R tau protein is confirmed by western blot with a 4R tau-specific antibody and with a total tau antibody in combination with λ phosphatase treatment ([Figures 2](#fig2){ref-type="fig"}F and 2G).Figure 2*MAPT* IVS10+16 Neurons Display Inclusion of Exon 10 at mRNA and Protein Level(A--C) RT-qPCR on NPCs (DIV31) and differentiated neurons at different time points, using primers detecting: 4R tau, *MAPT* exon 10 (A); 3R tau, *MAPT* exon 9--11 (B); or total tau, total *MAPT* (C). Neurons were lysed 3, 5, and 7 weeks after final plating of NPCs and correspond to DIV51, DIV65, and DIV80 from iPSC differentiation. ^∗^p \< 0.05, ^∗∗^p \< 0.01, and ^∗∗∗^p \< 0.001 (compared with NPC control, Kruskal-Wallis test with Dunn\'s post hoc analysis, n = 3). CTR, control.(D) Immunofluorescent staining with antibodies against MAP2 and TAU (DAKO) on mutant and control (DIV51) neurons. DAPI was used to stain the nucleus. Scale bar represents 100 μm.(E) Western blot for total tau (DAKO) shows no difference between control and mutant neurons (DIV80; n = 4; p = non-significant \[NS\], 1-way ANOVA).(F) Western blot on DIV65 control and mutant neurons using specific 3R tau and 4R tau antibodies. For (E) and (F), actin and β3-tubulin antibodies were used as loading control.(G) Western blot on DIV65 control and mutant neurons using the DAKO total tau antibody shows presence of both 3R and 4R tau isoforms in mutant neurons, after λ phosphatase treatment. A tau ladder with all six isoforms is included.See also [Figure S1](#mmc1){ref-type="supplementary-material"}.

Whole-Transcriptome Analysis Reveals Differences in Neuronal Subtypes and Cell-Cycle-Related Transcription Factors in IVS10+16 Neurons {#sec2.3}
--------------------------------------------------------------------------------------------------------------------------------------

To explore the potential effect of *MAPT* IVS10+16 and P301S mutations separately, all mutant and isogenic control iPSC-derived NPCs and neurons were subjected to microarray analysis. Principal component analyses of DIV31 NPCs and DIV65 neurons reveal that the largest proportion of all differentially expressed genes is linked to the IVS10+16 mutation (47% principal component 1 \[PC1\] at DIV31 and 78% PC1 at DIV65), while a smaller percentage corresponds to differences due to the P301S mutation (spectral maps in [Figures 3](#fig3){ref-type="fig"}A and 3B). Therefore, we first focused on the differences between control and mono-allelic IVS10+16 (+/−) neurons and found that 10.98% of all tested genes between these two groups are significantly different at the NPC stage, while 34.47% are significantly different at DIV65 (Volcano plots; [Figures 3](#fig3){ref-type="fig"}A and 3B). Gene Ontology Biological Processes (GOBP) such as forebrain cortex development, limbic system and hippocampus neuronal development, forebrain regionalization, and neuron fate commitment are altered, suggesting that control and mutant neurons correspond to different neuronal cell types that may be representative for different brain areas. This is reflected by a significantly reduced expression of forebrain and glutamatergic markers in IVS10+16 neurons ([Figures 3](#fig3){ref-type="fig"}C and [S2](#mmc1){ref-type="supplementary-material"} and [Table S1](#mmc1){ref-type="supplementary-material"}). On the other hand, limbic, GABAergic, and basal ganglia markers are upregulated in all mutant IVS10+16 neurons ([Figures 3](#fig3){ref-type="fig"}D and [S2](#mmc1){ref-type="supplementary-material"} and [Table S1](#mmc1){ref-type="supplementary-material"}). Immunofluorescent staining and quantification of TBR1, VGlut2, ISL1, and NKX2-1 proteins confirms the difference in neuronal subtypes between control and IVS10+16 neurons ([Figure 3](#fig3){ref-type="fig"}E).Figure 3Neuronal Subtype Differences Related to the *MAPT* IVS10+16 Mutation, by Whole-Transcriptome Analysis(A and B) Microarray on control and mutant NPCs (A) and DIV65 neurons (B) followed by principal component analysis reveals that the largest difference (47% at NPC stage and 78% at neuron stage; n = 3 biological replicates) is due to the presence of the IVS10+16 mutation while a lower percentage of differences is explained by the P301S mutation (22% at NPC stage and 8% at neuron stage; n = 3 biological replicates). PC, principal component.(C and D) Heatmaps showing the separate clustering of control and all IVS10+16 mutant cells regarding glutamatergic and GABAergic markers.(E) Immunofluorescent staining on control and mutant NPCs and neurons shows an increase of NKX2-1 and ISL1 proteins in IVS10+16-carrying NPCs (DIV31) (NKX2-1, p \< 0.0001, n = 3; and ISL1, p \< 0.0001, n = 3) and a reduction of TBR1 and VGlut2 proteins in IVS10+16-carrying neurons (DIV51-65) (TBR1, p = 0.0038, n = 3; and VGlut2, p = 0.0026, n = 3), compared with the control (CTR). CTIP2 is present similarly in both control and mutant neurons (p = NS; n = 3). Scale bar represents 100 μm. One-way ANOVA for ISL1, TBR1, VGlut2, and CTIP2, and Kruskal-Wallis test for NKX2-1. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, ^∗∗∗∗^p \< 0.0001.See also [Table S1](#mmc1){ref-type="supplementary-material"} and [Figures S2](#mmc1){ref-type="supplementary-material"} and [S3](#mmc1){ref-type="supplementary-material"}.

Furthermore, top affected Gene Ontology Molecular Functions (GOMF) at DIV31 and DIV65 include RNA polymerase II activating transcription factor, E-box binding, and transcriptional repressor activity. Several transcription factors and cell-cycle-related genes are significantly different in IVS10+16 neurons ([Figure 4](#fig4){ref-type="fig"}A and [Table S1](#mmc1){ref-type="supplementary-material"}), suggesting a potential difference in the proliferation potential of IVS10+16 NPCs. To test the proliferation potential of mutant and control NPCs, 5-ethynyl-2\'-deoxyuridine (EdU) staining was performed in combination with the nuclear marker DAPI and the neuronal marker β3-tubulin. Neurons with the IVS10+16 mutation (DIV51) display a significantly reduced percentage of EdU-positive cells (p \< 0.01; n = 3), less cells in general (DAPI counts; p \< 0.01; n = 3), and an increased β3-tubulin-positive area compared with control neurons, while the same number of NPCs was plated ([Figures 4](#fig4){ref-type="fig"}B and 4C).Figure 4*MAPT* IVS10+16 NPCs Display a Reduced Proliferation Potential(A) Heatmap showing the differences in clustering between control and IVS10+16 NPCs and neurons regarding transcription factor expression.(B and C) Immunofluorescent EdU staining in combination with the neuronal marker β3-tubulin and nuclear marker DAPI. There is no difference in the amount of DAPI and EdU-positive cells at the NPC stage (n = 3; p = NS) while there is a significant reduction of proliferating cells in all mutant lines 3 weeks after plating (DIV51; n = 3; p \< 0.001), and an increase in β3-tubulin-positive area normalized to cell count (DIV51, n = 3; p = 0.0075). Scale bar represents 100 μm. ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, and ^∗∗∗∗^p \< 0.0001 one-way ANOVA for DIV51 samples and Kruskal-Wallis for NPCs.See also [Table S1](#mmc1){ref-type="supplementary-material"} and [Figure S3](#mmc1){ref-type="supplementary-material"}.

Finally, the WNT protein binding pathway ([GO:0017147](http://amigo1.geneontology.org/cgi-bin/amigo/term_details?term=GO:0017147){#intref0010}) is also affected in IVS10+16 mutant NPCs and neurons. At the NPC stage, there are decreased transcript levels of *WNT*-related genes such as *WLS*, *DKK3*, *WNT7B*, *FZD7*, *ROR1*, and *APCDD1*, while *WNT7A* and *FZD5* transcripts are upregulated ([Table S2](#mmc1){ref-type="supplementary-material"} and [Figure S2](#mmc1){ref-type="supplementary-material"}). At DIV65, there is upregulation of some additional WNT-related genes such as *GSK3B*, *WNT4*, *AXIN2*, *FZD3*, while *FZD8* and *FZD2* are downregulated. Notably, in IVS10+16 neurons, the WNT ligand secretion mediator *WLS* is downregulated at the NPC stage and upregulated at DIV65, while *SFRP1* is upregulated in NPCs and downregulated in differentiated neurons. When looking at differentially expressed genes of the sonic hedgehog (SHH) pathway, we found that *LRP2*, *PTCH1*, *PTCHD1* are significantly upregulated in mutant NPCs and neurons, while *CEP76* and *CAV1* are downregulated ([Table S2](#mmc1){ref-type="supplementary-material"} and [Figure S2](#mmc1){ref-type="supplementary-material"}). These data suggest that WNT and SHH signaling pathways are different in control and IVS10+16-derived neural cells and that there is a complex regulation of the genes that are involved in these pathways.

To evaluate whether these observed phenotypes are a consequence of 4R tau expression, we used adeno-associated viruses (AAV6) to overexpress the longest isoform of 4R tau (2N4R) or a negative control (GFP) in control NPCs followed by evaluation of proliferation potential and some selected genes involved in cell cycle control and WNT/SHH pathways. Since these NPCs (DIV31) were already "primed" toward a cortical fate, we did not evaluate neuronal subtype changes after 4R tau overexpression. Three weeks after transduction of control cortical NPCs, there is no difference in proliferation potential and mRNA levels of the selected genes between 4R tau overexpressing neurons and controls ([Figure S3](#mmc1){ref-type="supplementary-material"}). This suggests that, in our system, the observed phenotypes are not due to the expression of 4R tau.

Heterogeneous Expression of *MAPT* with and without Exon 10 in Human Cortex at the Single-Cell Level {#sec2.4}
----------------------------------------------------------------------------------------------------

The *MAPT* IVS10+16-induced neuronal subtype changes in our *in vitro* neuronal model prompted us to look at tau isoforms with and without exon 10 in the neuronal population of a healthy human cortex. Therefore, we used a publicly available dataset generated recently by [@bib25]. For their study, single-cell transcriptome analysis was performed on isolated nuclei from postmortem human cerebral cortex. Unbiased principal component analysis separates interneurons and excitatory neurons into two major clusters, after color mapping with the glutamatergic marker SLC17A7 and the GABAergic marker GAD1 ([Figure 5](#fig5){ref-type="fig"}A). When coloring the summated isoforms of *MAPT* (*ENSEMBL* ENSG00000186868) with exon 10 (*MAPT_ex10*) and *MAPT* without exon 10 (*MAPT_no_ex10*), there was no clear separation into cell clusters and we did not find a correlation of *MAPT_ex10* or *MAPT_no_ex10* with any of the glutamatergic or interneuron markers tested ([Figures 5](#fig5){ref-type="fig"}B and [S4](#mmc1){ref-type="supplementary-material"}). However, we observed a positive correlation at the single-cell level between the interneuron markers *GAD1* and *GAD2* as well as between the excitatory glutamatergic genes *SLC17A7*, *TBR1*, and *SATB* and a negative correlation between the interneuron and excitatory markers, suggesting good quality of the data and the analysis tools used ([Figure 5](#fig5){ref-type="fig"}B). This suggests that, in the adult human cortex, 4R tau mRNA is present in both interneurons and excitatory neurons, although with different expression levels.Figure 5Single-Cell RNA Sequencing Analysis of Cerebral Cortex Shows Heterogeneous Expression of *MAPT* with and without Exon 10(A) Principal component analysis shows clustering of single cells into two populations that are positive for either the interneuron marker *GAD1* or the excitatory marker *SLC17A7*, when highlighting these markers.(B) Correlation plots showing GABAergic markers *GAD1* and *GAD2*; the excitatory genes *SLC17A7*, *TBR1*, and *SATB2*; and summated *MAPT* isoforms either with or without exon 10. There is no correlation between any of the neuronal subtype markers and *MAPT* isoforms.See also [Figure S4](#mmc1){ref-type="supplementary-material"}. Corr., correlation.

Neurons of Patients with the IVS10+16 Mutation Display a Similar Phenotype as ZFN-Gene-Edited IVS10+16 Neurons {#sec2.5}
--------------------------------------------------------------------------------------------------------------

As we were unable to link our observed phenotypes to 4R tau expression only, we evaluated whether these phenotypes could be confirmed in FTDP-17 patient-derived cells with the same IVS10+16 mutation. Therefore, iPSCs from two different *MAPT* IVS10+16 patients ([@bib39]) were differentiated in parallel with our ZFN-gene-edited *MAPT* IVS10+16 (+/−) and control iPSCs and subjected to microarray analysis. Only the mono-allelic ZFN-gene-edited iPSC line was chosen since the mutation is mono-allelic in patients as well. The result of this analysis shows that a large part of the variance (PC1 = 56%) is explained by the presence or absence of exon 10 ([Figure 6](#fig6){ref-type="fig"}A) as all three mutants cluster together at the opposite site of the Sigma control. The remainder (PC2 = 23%) of the variance is covered by differences among the two different patients and the ZFN-edited neurons. Overlap analysis between all three mutant neurons (DIV65; patient and ZFN edited) compared with the Sigma parental control, revealed that 1,983 genes are upregulated and 2,518 genes are downregulated in all mutants compared with the control ([Figure 6](#fig6){ref-type="fig"}B). Notably, the previously identified GOBP and GOMF pathways that are affected in the gene-edited lines are confirmed in these patient-derived neurons. Likewise, these patient-derived neurons show a reduction in glutamatergic genes and an upregulation of GABAergic markers together with differentially expressed transcription factor genes, WNT/SHH signaling, and WNT protein binding pathways ([Figure 6](#fig6){ref-type="fig"}C and [Table S2](#mmc1){ref-type="supplementary-material"}) compared with the Sigma control.Figure 6Patient-Derived *MAPT* IVS10+16 Neurons Display a Similar Phenotype as ZFN-Gene-Edited *MAPT* IVS10+16 Neurons(A) Microarray on control, ZFN-gene-edited, and two different patient-derived *MAPT* IVS10+16 neurons (DIV65) followed by principal component analysis (PC1 = 56% and PC2 = 23%; n = 3 biological replicates).(B) Overlap analysis between all mutants compared with control. In all three mutants, 1,983 common genes are upregulated and 2,518 common genes are downregulated compared with the control.(C) Heatmaps showing the separate clustering of control and mutant cells, focusing on glutamatergic and GABAergic markers.See also [Tables S2--S4](#mmc1){ref-type="supplementary-material"}.

Finally, we also evaluated whether some other well-known neurodegenerative disease-related genes are affected in our *MAPT* IVS10+16 mutant NPCs and neurons, compared with the control. The AD-related *APOE* gene is significantly downregulated in all mutant lines. When looking at *MAPT* exon 10 splicing mediators (reviewed in [@bib30]), we detect differential expression of *SRSF1*, *SRSF3*, *SRSF4*, *SRSF6*, *SRSF7*, *CELF3*, *CELF4*, *NOVA1*, and *SWAP70* ([Table S3](#mmc1){ref-type="supplementary-material"}), confirming that the splicing machinery around *MAPT* exon 10 is differentially regulated in IVS10+16 mutant and control cells. Regarding FTD-related genes, we found a significant increase in *TARDBP* (TDP-43) at DIV65, while *GRN* was significantly lower at the NPC stage in all *MAPT* IVS10+16 cells ([Table S4](#mmc1){ref-type="supplementary-material"}). Remarkably, the Parkinson disease (PD)-related gene *CHCHD2* is also significantly downregulated in all mutant lines, while *GAK* is upregulated.

Thus, both ZFN-engineered and patient-derived IVS10+16 neurons show overlapping expression patterns with regard to neuronal subtype definition; WNT/SHH signaling; transcription factor expression; and some selected AD, PD, and FTD-related genes.

Increased Burst Frequency in IVS10+16 Neurons with the Additional P301S Mutation {#sec2.6}
--------------------------------------------------------------------------------

Aiming for a more pronounced FTDP-17-related phenotype, we generated a double-mutant iPSC line, adding the pro-aggregant P301S mutation in *MAPT* exon 10 on top of the intronic IVS10+16 mutation. Since the mutation was introduced on a biallelic IVS10+16 background, only the IVS10+16 biallelic single-mutant line, expressing both wild-type 3R and 4R tau and largely consisting of the same neuronal subtypes ([Figure 3](#fig3){ref-type="fig"}), was chosen as a control for comparisons in this set of experiments. Microarray data reveal that 1,341 genes are differentially expressed at the NPC stage (DIV31), 664 genes at DIV51, 574 genes at DIV65, and 762 genes at DIV80 ([Figure S5](#mmc1){ref-type="supplementary-material"}). The most prominently affected function at the NPC stage (GOMF) reveals calcium channel regulator activity, represented by downregulation of [CACNA2D3](http://www.ncbi.nlm.nih.gov/gene/55799){#intref0015}, *NRXN3*, and *PRKCB* at all time points, while *S100A10* is upregulated ([Figure S5](#mmc1){ref-type="supplementary-material"} and [Table S5](#mmc1){ref-type="supplementary-material"}). To study a potential effect on calcium activity, live cell calcium imaging with Fluo-4 was performed on neurons with and without P301S mutation. The burst frequency of the neurons with P301S mutation is significantly higher (p \< 0.01, n = 3) than in neurons expressing wild-type tau isoforms ([Figure 7](#fig7){ref-type="fig"}A), suggesting a hyperexcitable phenotype.Figure 7*MAPT* IVS10+16/P301S Neurons Display Early FTDP-17-Related Phenotypes(A) Live cell calcium imaging using Fluo-4 shows an increased burst frequency in P301S/IVS10+16 mutant neurons (DIV65) compared with IVS10+16 controls (n = 3; p \< 0.01).(B and C) AlphaLISA revealing an increased signal for aggregated (hTAU10/hTAU10) tau in P301S mutant neurons (B), only after seeding with K18 (n = 3; p \< 0.0001), while total tau levels (C) are not affected (HT7/hTAU10) (p = NS).(D) Live imaging of K18-pHrodo uptake in combination with Cell Mask reveals no differences between control and mutant neurons (DIV65; n = 4; p = NS).(E) Live imaging using LysoTracker shows a decreased lysosomal intensity in P301S mutant neurons compared with controls (DIV65; n = 4; p \< 0.0001). Representative images for K18-Phrodo and LysoTracker are shown. Scale bars represent 50 μm.(F and G) TUNEL staining and β3-tubulin staining showing increased apoptosis in P301S mutant neurons compared with control without affecting the β3-tubulin-positive area (DIV65); n = 3, p = 0.042 for (F); n = 4 and p = 0.10 for (G).Scale bars represent 100 μm. ^∗^p \< 0.05, ^∗∗^p \< 0.01, and ^∗∗∗∗^p \< 0.0001; t test for (A) and (F), Mann-Whitney test for (D), (E), and (G); two-way ANOVA for (B) and (C). See also [Figures S5](#mmc1){ref-type="supplementary-material"} and [S6](#mmc1){ref-type="supplementary-material"} and [Table S5](#mmc1){ref-type="supplementary-material"}.

P301S-Carrying Neurons Display Tau Oligomerization after Seeding with K18 Fibrils {#sec2.7}
---------------------------------------------------------------------------------

Both patient-based and experimental evidence ([@bib2], [@bib15], [@bib5], [@bib37]) have shown the presence of tau aggregates and NFTs in P301S neurons. In our wild-type and P301S mutant neurons, we did not observe spontaneous formation of tau aggregates after an extended culturing period (DIV100) (not shown), measured by the highly sensitive AlphaLISA technology as previously described ([@bib40], [@bib29]). Therefore, we decided to trigger oligomerization or aggregation by adding recombinantly expressed preformed human mutant (P301L) K18 fibrils, representing the 4R tau microtubule binding domain that has been described to seed tau aggregation ([@bib15], [@bib40]). AlphaLISA to detect oligomerization and aggregation of tau (hTAU10/10) already shows an increased signal (p \< 0.0001; n = 3) in neurons expressing P301S tau and treated with K18-P301L seeds 5 weeks after seeding, but not in wild-type IVS10+16 neurons ([Figure 7](#fig7){ref-type="fig"}B). Note that there is also no increase in AlphaLISA signal when wild-type neurons are treated with wild-type K18 seeds ([Figure S6](#mmc1){ref-type="supplementary-material"}). With the aim to better characterize the nature of this increased hTAU10/10 signal, Sarkosyl extraction followed by western blot (HT7 antibody) was performed on IVS10+16/P301S neurons with and without K18-P301L fibrils. We failed to detect insoluble tau ([Figure S6](#mmc1){ref-type="supplementary-material"}C), which is in contrast to what we have previously shown in our virally induced tau aggregation model ([@bib40]). Therefore, this might suggest that the increased AlphaLISA signal in the current model more likely reflects the presence of dimers or oligomers in P301S-carrying neurons. AlphaLISA for total tau (HT7/hTAU10) shows that total tau levels are not affected by K18 seeding ([Figure 7](#fig7){ref-type="fig"}C). The selective increase in the hTAU10/10 AlphaLISA signal in P301S mutant neurons is not due to a difference in uptake of the K18 seeds, as a similar intensity of pHrodo-labeled K18 is detected in both control (IVS10+16) and IVS10+16/P301S neurons (p = non-significant, n = 4) ([Figure 7](#fig7){ref-type="fig"}D). However, a decreased LysoTracker spot intensity is observed in DIV65 IVS10+16/P301S mutant neurons compared with IVS10+16 control neurons, indicative of an increased lysosomal pH (p \< 0.0001; n = 4) ([Figure 7](#fig7){ref-type="fig"}E). To evaluate whether the above-described P301S-related increases in burst frequency and lysosomal pH affect the general health of the neurons, the number of apoptotic cells and the neuronal network area were quantified using TUNEL staining and β3-tubulin staining. Indeed, more apoptotic neurons are counted in DIV65 P301S-carrying neurons ([Figure 7](#fig7){ref-type="fig"}F), compared with their respective control (p = 0.042; n = 3), without affecting the neuronal network at this time point ([Figure 7](#fig7){ref-type="fig"}G).

Discussion {#sec3}
==========

We have successfully engineered iPSC lines containing the *MAPT* IVS10+16 mutation with and without additional P301S mutation using ZFN technology. The pathological IVS10+16 mutation was selected for its potency to fasten the inclusion of *MAPT* exon 10 ([@bib14]), while the pro-aggregant P301S mutation was chosen to generate an aggressive FTDP-17 model to complement several published *in vitro* and *in vivo* tau P301S systems ([@bib15], [@bib28], [@bib43]).

Differentiated neurons with the *MAPT* IVS10+16 mutation expressed 4R tau at both mRNA and protein levels, in alignment with published data on IVS10+16 patient iPSC-derived neurons ([@bib19], [@bib39]). Moreover, since *MAPT* IVS10+16 neurons express wild-type 4R tau, these neurons provide the best control for our double-mutant *MAPT* IVS10+16/P301S neurons, expressing 4R tau with the P301S mutation, and provide the opportunity to study mutation-specific phenotypes.

The *MAPT* IVS10+16 Mutation Drives Neurodevelopmental Phenotypes {#sec3.1}
-----------------------------------------------------------------

Whole-transcriptome analysis, evaluating the effects of the *MAPT* IVS10+16 mutation, revealed differences in forebrain cortex development, limbic system, and neural fate commitment as the main affected pathways. These data suggest that IVS10+16 mutant and control neurons represent different neuronal subtypes reminiscent of different parts of the brain. The reduction of cortical glutamatergic markers and the increase of interneuron and basal ganglia markers was confirmed at the protein level. These findings could be confirmed in iPSC-derived neurons from two different IVS10+16 patients, suggesting that these effects are not due to an off-target effect of the ZFN technology. An increasing amount of evidence suggests that tau isoforms with and without exon 10 might be differentially expressed in different neuronal subtypes, although with an overall ratio (4R/3R tau) of one in the whole brain. For example, mRNA expression data in different healthy brain regions revealed that the globus pallidus has the highest relative 4R tau expression, while the frontal cortex shows the lowest 4R tau expression ([@bib27]). Furthermore, 4R tau expression in iPSC-derived cortical neurons seems to take a long time ([@bib20], [@bib39]), while iPSC-derived dopaminergic neurons express different 4R tau isoforms within a relatively short time frame ([@bib3]), suggesting that different neuronal subtypes express different levels of the different tau isoforms at certain time points. In this study, we analyzed data from single-cell RNA sequencing on healthy adult postmortem cerebral cortex generated by [@bib25] and found a huge variation in the amount of *MAPT* transcripts with and without exon 10, independently of the neuronal subtype. Both excitatory neurons and interneurons expressed 4R tau at variable levels. Note that, for our analyses, we did not consider potential differences between Brodmann areas. More in-depth single-cell transcriptomics analysis on all different human brain areas and at different stages of brain development would provide more insight into the expression pattern of all tau isoforms in adult brain and during brain development.

Besides neuronal subtype differences, a reduced proliferation of IVS10+16 NPCs is observed and an increased β3-tubulin-positive neuronal network area, suggesting faster differentiation and maturation of IVS10+16 neurons, which is in line with the early maturation of mutant *MAPT* iPSC neurons that has been observed before, although with different mutations ([@bib20]). In our study, the reduced proliferation capability could not be linked to the expression of 4R tau as AAV6-induced overexpression of 4R tau did not reduce the proliferation potential compared with controls. This is in contrast to what has been published before in some *in vitro* and *in vivo* studies ([@bib35], [@bib6]) and is potentially due to differences in the various systems used.

An increasing amount of evidence suggests that neurodegenerative diseases such as AD and FTD are linked with aberrant WNT signaling ([@bib32], [@bib33], [@bib22]). Also in our study, the WNT signaling pathway is affected in neurons (and NPCs) with the IVS10+16 mutation. Several *WNT*, *SHH*, and *FZD* genes are differentially expressed and *GSK3β* is significantly upregulated in IVS10+16 tau-expressing neurons, reinforcing the link between FTDP-17 mutations, tau pathology, and GSK3β. This differential expression takes place as early as in the developmental stage, long before the formation of NFTs.

The Additional P301S Mutation in 4R Tau Induces Additional Phenotypes that Can Be Associated with Neurodegeneration {#sec3.2}
-------------------------------------------------------------------------------------------------------------------

We also characterized the ZFN-engineered double-mutant IVS10+16/P301S neurons in comparison with the single-mutant IVS10+16 neurons. Live cell calcium imaging revealed an increased burst frequency, suggesting hyperexcitability of the neurons carrying the P301S mutation. These data are in line with published studies showing neuronal hyperexcitability and epileptic seizures in P301S animal models and FTDP-17 patients with this mutation ([@bib11], [@bib37]).

Another well-recognized characteristic of P301S-related FTDP-17 is tau hyperphosphorylation and the formation of NFTs. Although we did not see spontaneous formation of tau aggregates in our neuronal cultures (up to DIV100), we could induce tau oligomerization after seeding with K18 (P301L) in 4R tau-expressing neurons with the P301S mutation. Notably, the AlphaLISA hTAU10/10 signal was remarkably lower than in the AAV-induced iPSC-neuronal model that we have previously reported ([@bib40]) and we did not find evidence for the presence of insoluble tau, suggesting that soluble dimers or smaller oligomers are present in our current model. More in-depth analysis using more specialized technologies would be helpful to further characterize these non-monomeric tau species. Potentially, this lower hTAU10/10 AlphaLISA signal is due to the relatively low levels of 4R tau protein compared with 3R tau protein in our neurons at the chosen time points. Alternatively, the difference in neuronal subtypes might play a role as well, as excitatory neuronal cell types might intrinsically be more prone to the formation of NFTs.

Furthermore, the increased lysosomal pH that we observed in P301S-expressing neurons potentially affects the clearance of tau oligomers and formation of NFTs at a later stage, as suggested by others using tau-expressing cell lines ([@bib16], [@bib42]). Finally, increased apoptosis was observed in P301S-carrying neurons, potentially resulting from the hyperexcitability and increased lysosomal pH and in line with published findings ([@bib26], [@bib43]).

Summary and Conclusion {#sec3.3}
----------------------

FTDP-17 linked with tau is a complex neurodegenerative disorder, with a mutation- and patient-dependent plethora of neurological and clinical manifestations (reviewed in [@bib13]) and with different areas of the brain being affected. In the present study, we observed neuronal subtype differences due to the IVS10+16 mutation, which might highlight the neuronal subtypes and cortical layers that are predominantly affected in these patients, such as the medial temporal lobe (limbic system) and basal ganglia ([@bib41]).

Since *MAPT* IVS10+16 FTD patients inherently carry the mutation already during developmental stages, there must be compensatory mechanisms such as morphogens or growth factors by supporting cell types in the brain that keep patients cognitively normal until the onset of disease. However, a neurodevelopmental predisposition to dementia has been observed in non-demented pre-symptomatic family members with an FTDP-17 mutation ([@bib12]), and microdeletions surrounding the *MAPT* locus have been linked to intellectual disability, suggesting that tau might be involved in the regulation of early functions during development ([@bib34]). Remarkably, FTDP-17-related progranulin haplo-insufficiency has also been linked with dysregulation of WNT signaling pathways ([@bib33], [@bib1]) and aberrant cortical differentiation of iPSCs ([@bib31]).

Accordingly, WNT signaling is indispensable for normal brain development and neural cell fate commitment ([@bib17]) and its link with the IVS10+16 mutation suggests that developmental aberrations might underlie the regional neuronal selectivity and vulnerability that are characteristic for FTDP-17-related tauopathies. Indeed, an aberrant WNT/SHH signaling pathway, as suggested by whole-transcriptome analysis, might cause the observed differences in neuronal cell types in our purely neuronal *in vitro* model and therefore might exacerbate the phenotypes and mechanisms that are potentially linked with the *MAPT* IVS10+16 mutation, as compensatory factors and additional cell types and cellular interactions are lacking in our current model. Also, analysis on postmortem IVS10+16 patient brain tissue would be interesting, to explore whether similar affected pathways can be identified as in our *in vitro* model.

We conclude that the set of gene-edited iPSC lines with *MAPT* IVS10+16 and *MAPT* IVS10+16/P301S mutations that we described could serve as a platform to identify new targets for drug development and to reveal the mechanisms underlying FTDP-17 and other tauopathies. All ZFN-engineered iPSC lines are available to the scientific community via EBiSC ([https://cells.ebisc.org](https://cells.ebisc.org/){#intref0020}) and could therefore be used by others to further identify and/or confirm *MAPT* IVS10+16 and/or P301S-related phenotypes in comparison with the appropriate isogenic control.

Experimental Procedures {#sec4}
=======================

Human iPSC Culture and Differentiation into Cortical Neurons {#sec4.1}
------------------------------------------------------------

Human iPSCs were cultured feeder free and fed daily with fresh mTeSR™1 medium (Stem Cell Technologies). Cells were passaged with EDTA (Gibco) at confluency. Differentiation into NPCs and cortical neurons was performed using an adapted dual SMAD inhibition protocol ([@bib24], [@bib36]). More information can be found in the [Supplemental Information](#app3){ref-type="sec"}.

RNA Extraction and RT-qPCR {#sec4.2}
--------------------------

Cells were lysed with RLT buffer (Qiagen) supplemented with 1% β-mercaptoethanol. RNA extraction was done using the RNeasy mini kit (Qiagen) followed by cDNA preparation using SuperScript III (Life Technologies). More detailed information on qRT-PCR, microarray analysis, and single-cell data analysis can be found in the [Supplemental Information](#app3){ref-type="sec"}. Note that patient 1 and patient 2 in this manuscript refer to iPSC clones V97 and TSM.

Western Blot {#sec4.3}
------------

Cells were washed gently with PBS and lysed in radioimmunoprecipitation assay (RIPA) buffer (Gibco) supplemented with protease and phosphatase inhibitors (HALT; Invitrogen). Protein was loaded on Bis-Tris gels and, after SDS PAGE, gels were blotted on nitrocellulose and blocked for 1 hr at room temperature (RT) in Tris-buffered saline (TBS) 0.1% Tween 20 supplemented with 5% milk. Detection was done with horseradish peroxidase-labeled secondary antibodies and the West Dura or West Femto enhanced chemiluminescence kit. More information can be found in the [Supplemental Information](#app3){ref-type="sec"}.

Immunocytochemistry {#sec4.4}
-------------------

Cells were fixed for 15 min using 4% paraformaldehyde and 4% sucrose in PBS, washed, and permeabilized for 15 min with Triton X-100 (0.25%) in TBS (50 mM TrisHCl,150 mM NaCl, pH 7,5). After 30 min blocking with 5% normal donkey serum in TBS-Triton-X100 (0.25%), cells were incubated overnight in blocking buffer at 4°C with the following primary antibodies: rabbit anti-VGLUT2, rabbit anti-OCT4, mouse anti- ISL1, mouse anti-RD4, mouse anti-NANOG, mouse and rabbit anti-TUBB3, rabbit anti-TTF1, rabbit anti-TBR1, and rat anti-CTIP2. Subsequently, cells were washed with TBS and incubated for 1 hr at RT with Alexa Fluor 488, Alexa Fluor 594, or Alexa Fluor 647 secondary antibodies (Invitrogen). DAPI or Hoechst was used to stain the nuclei. The immunocytochemistry based Click-iT Plus EdU Imaging Kit and TUNEL kit were used as per manufacturer\'s instructions to quantify the number of proliferating and apoptotic cells, respectively. Confocal images were taken with Opera Phenix (PerkinElmer) or CV7000 (Yokogawa) high-content imaging readers. Analysis was done using Columbus (PerkinElmer) and Phaedra (in-house developed open-source software available at [www.phaedra.io](http://www.phaedra.io){#intref0025}) ([@bib7]). More detailed information about antibodies can be found in the [Supplemental Information](#app3){ref-type="sec"}.

Live Imaging of pHrodo-488 K18 Fibril Uptake and Lysosomes {#sec4.5}
----------------------------------------------------------

Pre-aggregated K18 fibrils (40 μM K18:P301L-myc) were labeled with pHrodo Green STP ester (Molecular Probes) per manufacturer\'s instructions and purified (72 hr) using Slide-A-Lyzer dialysis cassettes (Thermo Fisher Scientific). Neurons were incubated overnight with 75 nM pHrodo-labeled K18 followed by live imaging with Opera Phenix and image analyses using Harmony Software. For visualization of lysosomes, neurons were incubated for 5 min with LysoTracker Red DND-99 (Life Technologies), Hoechst 33342, and CellMask Deep Red Plasma Membrane Stain (both Molecular Probes) followed by live imaging with Opera Phenix and image analyses using Harmony Software. More details on K18 preparation can be found in the [Supplemental Information](#app3){ref-type="sec"}.

Live Cell Calcium Imaging {#sec4.6}
-------------------------

Cells were loaded for 30 min (37°C and 5% CO~2~) with 1 μM Fluo-4-AM in Dulbecco\'s PBS containing calcium and magnesium and 10 mM glucose, followed by imaging with an inverted confocal laser scanning microscope and analysis using a custom-made MATLAB script. More details can be found in the [Supplemental Information](#app3){ref-type="sec"}.

AlphaLISA {#sec4.7}
---------

Cells in 96-well plates were lysed in 40 μL/well RIPA buffer with protease and phosphatase inhibitors (Roche). After 20--30 min of gentle shaking at RT, a 5 μL sample was mixed with 20 μL of biotinylated and acceptor-bead-conjugated antibodies in OptiPlate-384 (all Perkin Elmer). After 2 hr of incubation at RT, 25 μL of streptavidin donor beads were added at RT for 30 min followed by detection with the Envision plate reader. Raw values were normalized to transduced control samples (without fibrils) per plate. To allow the detection of aggregates, the monoclonal hTAU10 antibody was conjugated to both acceptor beads and biotin. To measure total tau levels, a biotinylated HT7 antibody was combined with acceptor-bead-conjugated hTAU10 (HT7/hTAU10) ([@bib40]).

Statistics {#sec4.8}
----------

Cells from three independent differentiations were used for all experiments. All data were acquired from at least three independent experiments (n), unless specified otherwise. Data are shown as the mean with SEM. Student\'s t test was used to compare two groups and one-way or two-way ANOVA was used to compare more than two groups (GraphPad Prism 6). Dunnet\'s or Sidak\'s post hoc test was used for multiple comparisons. When the data were not normally distributed or with unequal variance, non-parametric tests were used: a Mann-Whitney test for two groups and a Kruskal-Wallis test with Dunn\'s post hoc test for more than two groups. p values \< 0.05 were considered significantly different.
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